Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ARICEPT

« Back to Dashboard
Aricept is a drug marketed by Eisai Inc and is included in four NDAs. It is available from eight suppliers. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-four patent family members in fourteen countries.

The generic ingredient in ARICEPT is donepezil hydrochloride. There are thirty drug master file entries for this compound. Eight suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the donepezil hydrochloride profile page.

Summary for Tradename: ARICEPT

Patents:3
Applicants:1
NDAs:4
Suppliers / Packagers: see list31

Pharmacology for Tradename: ARICEPT

Clinical Trials for: ARICEPT

Aricept to Improve Functional Tasks in Vascular Dementia
Status: Active, not recruiting Condition: Stroke; Vascular Dementia; Memory Deficits

A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
Status: Completed Condition: Dementia With Lewy Bodies (DLB)

A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
Status: Completed Condition: Dementia With Lewy Bodies (DLB)

Pharmacokinetic Comparisons of Two Donepezil Formulations
Status: Completed Condition: Alzheimer Disease

Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
Status: Recruiting Condition: Alzheimer's Disease

Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition
Status: Completed Condition: Healthy

Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition
Status: Completed Condition: Healthy

Donepezil 10 mg Tablets Under Fed Conditions
Status: Completed Condition: Healthy

Donepezil 10 mg Tablets Under Fasting Conditions
Status: Completed Condition: Healthy

A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
Status: Recruiting Condition: Alzheimer's Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
ARICEPT
donepezil hydrochloride
SOLUTION;ORAL021719-001Oct 18, 2004DISCNNo<disabled><disabled>
Eisai Inc
ARICEPT ODT
donepezil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021720-002Oct 18, 2004RXYes7,727,548<disabled>Y <disabled>
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL022568-001Jul 23, 2010RXYes8,481,565<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ARICEPT

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-002Nov 25, 19964,895,841<disabled>
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-001Nov 25, 19964,895,841<disabled>
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL022568-001Jul 23, 20104,895,841<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ARICEPT

Drugname Dosage Strength RLD Submissiondate
donepezil hydrochlorideTablets23 mgAricept7/9/2013
donepezil hydrochlorideOrally Disintegrating Tablets5 mg and 10 mgAricept ODT6/30/2010

International Patent Family for Tradename: ARICEPT

Country Document Number Publication Date
South Korea100904602Jun 25, 2009
European Patent Office1830886Oct 10, 2012
Japan2008525313Jul 17, 2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc